PHOSPHODIESTERASE-5 (PDE-5) INHIBITOR
Adcirca is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to improve exercise in cases of pulmonary arterial hypertension. Adcirca may be referred to by its drug name, tadalafil.
Adcirca is a phosphodiesterase-5 (PDE-5) inhibitor. Adcirca inhibits the action of an enzyme called phosphodiesterase-5 (PDE-5), which works to control blood flow. In cases of pulmonary hypertension, Adcirca is believed to work by dilating the pulmonary arteries.
How do I take it?
Prescribing information states that Adcirca is taken once daily.
Adcirca comes in tablet form.
The FDA-approved label for Adcirca lists common side effects including headache.
Rare but serious side effects listed for Adcirca include loss of vision, hearing impairment, and painful or prolonged erections.
For more details about this treatment, visit:
Adcirca — Lung Biotechnology
Phosphodiesterase 5 inhibitors — Pulmonary Hypertension Association UK